IU Ventures

Amplified Sciences LLC is a molecular diagnostics company focused on the early detection of debilitating diseases, particularly pancreatic cancer and kidney disease. Utilizing an ultra-sensitive molecular sensing technology licensed from Purdue University, the company’s platform can detect disease markers at the single molecule level, enabling accurate diagnosis from bodily fluids such as urine and saliva. This versatile technology is designed for scalability to point-of-care applications, allowing for effective disease screening with a favorable cost structure. Amplified Sciences has developed a working prototype and has published proof of concept data, positioning itself to meet significant unmet medical needs in diagnostics. Founded in 2016 and based in West Lafayette, Indiana, the company was previously known as Nutrabiotix.

Plan Forward, LLC is an online platform that focuses on providing dental membership solutions for uninsured patients. Established in 2018 and headquartered in Indianapolis, Indiana, the company partners with dentists and dental practices to create customized in-office membership plans. This platform enables dental providers to offer their services without the complexities of traditional insurance, thereby improving patient access to quality care. Plan Forward's software facilitates the management of membership plans, enhances treatment acceptance, and fosters patient loyalty. It includes features such as pre-built dashboards and compliant membership agreements, making it easier for dental professionals to market their plans and grow their revenue.

Apexian Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Indianapolis, Indiana, focused on developing innovative compounds for cancer treatment. The company's lead product, APX3330, is an oral anticancer agent that targets the APE1/Ref-1 redox protein, a molecule implicated in various cancers, including those affecting the colon, lung, breast, and pancreas. Founded in 2007, Apexian Pharmaceuticals emerged from research conducted by Dr. Mark R. Kelley, which provided insights into the biological mechanisms associated with APE1/Ref-1. In addition to its work in oncology, the company is also exploring treatments for other conditions, such as bladder cancer, sarcomas, age-related macular degeneration, and inflammatory bowel disease. By focusing on the discovery and development of novel pharmaceuticals, Apexian aims to improve patient outcomes through targeted therapies.

Amplified Sciences LLC is a molecular diagnostics company focused on the early detection of debilitating diseases, particularly pancreatic cancer and kidney disease. Utilizing an ultra-sensitive molecular sensing technology licensed from Purdue University, the company’s platform can detect disease markers at the single molecule level, enabling accurate diagnosis from bodily fluids such as urine and saliva. This versatile technology is designed for scalability to point-of-care applications, allowing for effective disease screening with a favorable cost structure. Amplified Sciences has developed a working prototype and has published proof of concept data, positioning itself to meet significant unmet medical needs in diagnostics. Founded in 2016 and based in West Lafayette, Indiana, the company was previously known as Nutrabiotix.

Encamp, Inc. is a software company that focuses on automating environmental compliance and reporting for organizations in the United States. Founded in 2017 and based in Indianapolis, Indiana, Encamp's software solutions help businesses manage their environmental compliance requirements, track hazardous materials, and streamline reporting processes. One of its key offerings, Tier2, allows organizations to fill out and submit annual reports regarding hazardous chemicals, incorporating detailed information beyond the standard Tier 1 report. Additionally, Encamp provides tools for centralized environmental, health, and safety (EHS) information management, including compliance calendars, task reminders, and a comprehensive form library. Through its innovative technology, Encamp aims to assist businesses in effectively aligning their corporate operations with environmental regulations.

Diagnotes, Inc. is a digital healthcare company based in Indianapolis, Indiana, that specializes in enhancing communication and collaboration within the healthcare industry. Established in 2010, the company offers a clinical communication platform designed to facilitate secure messaging, provider scheduling, patient data management, and documentation of discussions. This platform is tailored to the needs of various stakeholders, including patients, physicians, care teams, hospitals, health systems, and physician practices, enabling them to efficiently manage all patient-related communications. Diagnotes' applications are intuitive and easily adopted, serving a diverse clientele that includes large health systems, community hospitals, long-term care facilities, and behavioral health organizations. The platform supports a range of functionalities, from simple messaging to telehealth consultations, ensuring effective communication among healthcare professionals and their patients on a unified, cloud-based system.

Canopy operates an online platform designed for frontline sales managers, providing tools to enhance sales performance and decision-making. The platform offers real-time data insights that help managers identify wins and losses at the individual seller level, enabling proactive coaching and support for sales representatives. By monitoring pipeline and rep data, Canopy alerts leaders to potential issues before they affect deals, thereby improving forecast accuracy and driving strategic change. The platform also highlights performance trends, allowing managers to track team dynamics and diagnose issues effectively. Originally known as Loupe Software, Inc., Canopy was incorporated in 2019 and is headquartered in Indianapolis, Indiana.

Encamp, Inc. is a software company that focuses on automating environmental compliance and reporting for organizations in the United States. Founded in 2017 and based in Indianapolis, Indiana, Encamp's software solutions help businesses manage their environmental compliance requirements, track hazardous materials, and streamline reporting processes. One of its key offerings, Tier2, allows organizations to fill out and submit annual reports regarding hazardous chemicals, incorporating detailed information beyond the standard Tier 1 report. Additionally, Encamp provides tools for centralized environmental, health, and safety (EHS) information management, including compliance calendars, task reminders, and a comprehensive form library. Through its innovative technology, Encamp aims to assist businesses in effectively aligning their corporate operations with environmental regulations.

Doxly, Inc. is a provider of transaction-management software specifically designed for law firms. Established in 2016 and headquartered in Indianapolis, Indiana, Doxly aims to transform the traditionally cumbersome process of managing legal transactions into a more streamlined and efficient experience. The platform enhances the transaction process by automating workflows, facilitating document-level collaboration, and offering tools for diligence, closing checklists, and transaction analytics. By focusing on the unique needs of legal professionals, Doxly seeks to improve client experiences and strengthen law practices, making it easier for attorneys to manage all aspects of their transaction work. As of August 2019, Doxly operates as a subsidiary of Freedom Solutions Group, LLC.

Diagnotes, Inc. is a digital healthcare company based in Indianapolis, Indiana, that specializes in enhancing communication and collaboration within the healthcare industry. Established in 2010, the company offers a clinical communication platform designed to facilitate secure messaging, provider scheduling, patient data management, and documentation of discussions. This platform is tailored to the needs of various stakeholders, including patients, physicians, care teams, hospitals, health systems, and physician practices, enabling them to efficiently manage all patient-related communications. Diagnotes' applications are intuitive and easily adopted, serving a diverse clientele that includes large health systems, community hospitals, long-term care facilities, and behavioral health organizations. The platform supports a range of functionalities, from simple messaging to telehealth consultations, ensuring effective communication among healthcare professionals and their patients on a unified, cloud-based system.

Cause.it Inc. is a company based in Indianapolis, Indiana, founded in 2011, that specializes in developing mobile applications aimed at enhancing engagement between higher education institutions and their alumni. The platform allows schools to connect with alumni by enabling them to create personalized affinity profiles based on their interests. This information helps institutions improve their engagement strategies and tailor fundraising campaigns more effectively. Cause.it seeks to modernize the fundraising landscape by moving away from traditional methods such as direct mail and telemarketing, instead focusing on digital solutions that provide a more streamlined and personalized experience for alumni. Additionally, the application offers tools for community volunteers to sign up for nonprofit service events, thus fostering a deeper connection between volunteers and organizations. Overall, Cause.it aims to simplify a fragmented market and enhance the donor experience through innovative digital tools.

Courseload, Inc. is an early-stage educational software company focused on providing digital course materials to students and educators. Its software-as-a-service (SaaS) platform significantly reduces the cost of textbooks and proprietary content by up to two-thirds while ensuring access to self-generated, open source, and fair use educational resources. This affordability can save students thousands of dollars over their undergraduate years, while also enhancing revenue for textbook publishers. The Courseload platform facilitates collaborative teaching and learning, which has been shown to improve educational outcomes through research supported by the National Science Foundation. With a commitment to making higher education more accessible and affordable, Courseload is expanding its services in the K-12 and higher education sectors, partnering with various universities and schools, including multiple Big Ten institutions and community colleges. The company's continued growth reflects its mission to provide significant savings to students while fostering improved learning experiences.

Aarden Pharmaceuticals is a small molecule drug discovery and development company. The company’s novel technology is a chemistry breakthrough that will enable it to make drugs against a previously un-druggable set of intracellular phosphatase (PTP) disease targets. The technology was developed in the laboratory of Dr. Zhong-Yin Zhang, Robert A. Harris Professor and chairman of biochemistry and molecular biology at the Indiana University School of Medicine. Zhang is an internationally recognized expert in the field of protein tyrosine phosphatases (PTPs). Aarden’s first programs are focused on infectious disease, cancer, and metabolic and autoimmune conditions.

Apexian Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Indianapolis, Indiana, focused on developing innovative compounds for cancer treatment. The company's lead product, APX3330, is an oral anticancer agent that targets the APE1/Ref-1 redox protein, a molecule implicated in various cancers, including those affecting the colon, lung, breast, and pancreas. Founded in 2007, Apexian Pharmaceuticals emerged from research conducted by Dr. Mark R. Kelley, which provided insights into the biological mechanisms associated with APE1/Ref-1. In addition to its work in oncology, the company is also exploring treatments for other conditions, such as bladder cancer, sarcomas, age-related macular degeneration, and inflammatory bowel disease. By focusing on the discovery and development of novel pharmaceuticals, Apexian aims to improve patient outcomes through targeted therapies.